P6. Abstract Title: Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review

Background Thrombosis is the major cause of morbidity and mortality in patients with polycythemia vera (PV). Aspirin, and phlebotomy with or without cytoreductive therapy are key components of PV management to reduce thrombotic risk. However, patients with PV are also at risk for hemorrhagic complications, especially in the context of thrombocytosis and acquired Von Willebrand factor deficiency. The net benefit of antithrombotic therapy for …